Drug Trial Radar · NCT01596751
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Jul 12, 2012
Primary completion
Jul 5, 2017
Study completion Jul 5, 2019
Sponsor
- Lead sponsor
- Hope Rugo, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Susan G. Komen Breast Cancer Foundation; Plexxikon
- First posted
- May 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.
Conditions
- Metastatic Breast Cancer
Interventions
PLX3397Drug
Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
EribulinDrug
Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of PLX3397 Given in Combination With Standard Dose Eribulin in Participants With Metastatic Breast Cancer (Phase 1b)Time frame: Up to Day 21
- Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) (Phase Ib)Time frame: Up to Day 21
- Percentage of Total Phase II Participants With Chemotherapy Pre-Treated Triple Negative Metastatic Breast Cancer Who Are Progression Free at 3 MonthsTime frame: Up to 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Duke University Cancer Center
Durham, North Carolina
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.